News

This phase Ib trial is designed to evaluate the tolerability, pharmacology and antiviral activity of PRO 140 in patients infected with HIV. PRO 140 binds CCR5, a principal

Spectrum filed a demand for arbitration and statement of claims with the American Arbitration Association. Spectrum said the demand was a response to GPC Biotech excluding Spectrum from

Tekturna was submitted for approval earlier in 2006 to become the first in a new class of high blood pressure medicines for more than a decade. The decision

As part of the agreement Schering-Plough will be responsible for all forward research and development activities, including clinical studies and regulatory filings, continuing its focus on developing hepatitis

Under the agreement, Trana will screen Southern Research’s extensive collection of nucleosides to identify anti-infectives.Trana’s screening assays identify compounds that interrupt the lifecycle of pathogens through a new

As part of this filing, Reliant submitted new data from the recently completed trial that evaluated the efficacy and safety of Omacor as an adjunct to diet and

Abbott’s cash tender offer to purchase all of the outstanding common stock of Kos expired on December 12, 2006. Abbot offered to acquire Kos last month for $3.7

Barr is seeking authorization to market a generic version of Thalomid 200mg tablets in the US. Celgene has approval to market Thalomid as a treatment in combination with

The new drug application includes the results of the company's phase III clinical program as well as the results of additional phase I and phase II studies. Indevus